Spyre Therapeutics (SYRE) Shares Outstanding (Weighted Average) (2015 - 2026)

Spyre Therapeutics has reported Shares Outstanding (Weighted Average) for 12 years, with the latest figure at $78.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 30.34% year-over-year to $78.5 million; the trailing twelve-month figure through Mar 2026 stood at $78.5 million (up 30.34% YoY), and the FY2025 full-year result was $64.1 million, up 75076.56% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $78.5 million, up from $64.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $78.5 million in Q1 2026, with the low at $16667.0 in Q3 2025.
• Historically, Shares Outstanding (Weighted Average) has averaged $31.6 million across 5 years, with a median of $21.6 million in 2023.
• The largest YoY upside for Shares Outstanding (Weighted Average) was 75076.56% in 2025 against a maximum downside of 99.96% in 2025.
• Spyre Therapeutics' Shares Outstanding (Weighted Average) stood at $3.2 million in 2022, then jumped by 114.0% to $6.9 million in 2023, then plunged by 98.76% to $85208.0 in 2024, then surged by 75076.56% to $64.1 million in 2025, then increased by 22.62% to $78.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $78.5 million (Q1 2026), $64.1 million (Q4 2025), and $16667.0 (Q3 2025), per Business Quant data.